These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 2807549)

  • 21. A bivalent conjugate vaccine containing PspA families 1 and 2 has the potential to protect against a wide range of Streptococcus pneumoniae strains and Salmonella Typhi.
    Kothari N; Kothari S; Choi YJ; Dey A; Briles DE; Rhee DK; Carbis R
    Vaccine; 2015 Feb; 33(6):783-8. PubMed ID: 25545593
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cholera toxin and its B subunit promote dendritic cell vaccination with different influences on Th1 and Th2 development.
    Eriksson K; Fredriksson M; Nordström I; Holmgren J
    Infect Immun; 2003 Apr; 71(4):1740-7. PubMed ID: 12654787
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunologic characteristics of a Streptococcus mutans glucosyltransferase B sucrose-binding site peptide-cholera toxin B-subunit chimeric protein.
    Laloi P; Munro CL; Jones KR; Macrina FL
    Infect Immun; 1996 Jan; 64(1):28-36. PubMed ID: 8557352
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of an internal permissive site in the cholera toxin B-subunit and insertion of epitopes from human immunodeficiency virus-1, hepatitis B virus and enterotoxigenic Escherichia coli.
    Bckström M; Holmgren J; Schödel F; Lebens M
    Gene; 1995 Nov; 165(2):163-71. PubMed ID: 8522171
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quantitative and qualitative analyses of serum antibodies elicited in adults by Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-tetanus toxoid conjugates.
    Schneerson R; Robbins JB; Parke JC; Bell C; Schlesselman JJ; Sutton A; Wang Z; Schiffman G; Karpas A; Shiloach J
    Infect Immun; 1986 May; 52(2):519-28. PubMed ID: 3516876
    [TBL] [Abstract][Full Text] [Related]  

  • 26. S.Typhi derived OmpC peptide conjugated with Vi-polysaccharide evokes better immune response than free Vi-polysaccharide in mice.
    Haque S; Sengupta S; Gupta D; Bhan MK; Kumar R; Khan A; Jailkhani B
    Biologicals; 2019 Nov; 62():50-56. PubMed ID: 31606267
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenicity of Vi capsular polysaccharide vaccine evaluated for three years in Korea.
    Kim YR; Yoo JH; Hur JK; Kang JH; Shin WS; Kang MW
    J Korean Med Sci; 1995 Oct; 10(5):314-7. PubMed ID: 8750055
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multicenter study for the evaluation of the antibody response against salmonella typhi Vi vaccination (EMPATHY) for the diagnosis of Anti-polysaccharide antibody production deficiency in patients with primary immunodeficiency.
    Sánchez-Ramón S; de Gracia J; García-Alonso AM; Rodríguez Molina JJ; Melero J; de Andrés A; García Ruiz de Morales JM; Ferreira A; Ocejo-Vinyals JG; Cid JJ; García Martínez JM; Lasheras T; Vargas ML; Gil-Herrera J; García Rodríguez MC; Castañer JL; González Granado LI; Allende LM; Soler-Palacin P; Herráiz L; López Hoyos M; Bellón JM; Silva G; Gurbindo DM; Carbone J; Rodríguez-Sáinz C; Matamoros N; Parker AR; Fernández-Cruz E;
    Clin Immunol; 2016 Aug; 169():80-84. PubMed ID: 27236002
    [No Abstract]   [Full Text] [Related]  

  • 29. Measurement of Typhi Vi antibodies can be used to assess adaptive immunity in patients with immunodeficiency.
    Evans C; Bateman E; Steven R; Ponsford M; Cullinane A; Shenton C; Duthie G; Conlon C; Jolles S; Huissoon AP; Longhurst HJ; Rahman T; Scott C; Wallis G; Harding S; Parker AR; Ferry BL
    Clin Exp Immunol; 2018 Jun; 192(3):292-301. PubMed ID: 29377063
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of a bivalent conjugate vaccine candidate against malaria transmission and typhoid fever.
    An SJ; Scaria PV; Chen B; Barnafo E; Muratova O; Anderson C; Lambert L; Chae MH; Yang JS; Duffy PE
    Vaccine; 2018 May; 36(21):2978-2984. PubMed ID: 29681410
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunization with the conjugate vaccine Vi-CRM₁₉₇ against Salmonella typhi induces Vi-specific mucosal and systemic immune responses in mice.
    Fiorino F; Ciabattini A; Rondini S; Pozzi G; Martin LB; Medaglini D
    Vaccine; 2012 Sep; 30(43):6111-4. PubMed ID: 22705173
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization.
    Klugman KP; Koornhof HJ; Robbins JB; Le Cam NN
    Vaccine; 1996 Apr; 14(5):435-8. PubMed ID: 8735556
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nasal immunization of mice with AFCo1 or AFPL1 plus capsular polysaccharide Vi from Salmonella typhi induces cellular response and memory B and T cell responses.
    Romeu B; Lastre M; Reyes L; González E; Borrero Y; Lescaille D; Pérez R; Nuñez D; Pérez O
    Vaccine; 2014 Dec; 32(51):6971-6978. PubMed ID: 25454865
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cross-reactive immune response elicited by parenteral Vi polysaccharide typhoid vaccine against non-typhoid Salmonellae.
    Pakkanen SH; Kantele JM; Herzog C; Kantele A
    Vaccine; 2014 Jan; 32(5):544-51. PubMed ID: 24342246
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lack of immune response to the Vi component of a Vi-positive variant of the Salmonella typhi live oral vaccine strain Ty21a in human studies.
    Tacket CO; Losonsky G; Taylor DN; Baron LS; Kopecko D; Cryz S; Levine MM
    J Infect Dis; 1991 Apr; 163(4):901-4. PubMed ID: 2010645
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Local and systemic antibody responses to dextran-cholera toxin B subunit conjugates.
    Bergquist C; Lagergård T; Lindblad M; Holmgren J
    Infect Immun; 1995 May; 63(5):2021-5. PubMed ID: 7537252
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Persistence of antibody titres three years after vaccination with Vi polysaccharide vaccine against typhoid fever.
    Tacket CO; Levine MM; Robbins JB
    Vaccine; 1988 Aug; 6(4):307-8. PubMed ID: 3188615
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of the antibody response in 110 healthy individuals who have been subject to Vi capsular polysaccharide vaccine.
    Dizer U; Görenek L; Güner O; Pehlivan T; Ozgüven V; Pahsa A
    Vaccine; 2002 Aug; 20(25-26):3052-4. PubMed ID: 12163256
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recombinant cholera toxin B subunit and gene fusion proteins for oral vaccination.
    Sanchez J; Johansson S; Löwenadler B; Svennerholm AM; Holmgren J
    Res Microbiol; 1990; 141(7-8):971-9. PubMed ID: 2101488
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunological evaluation of Vi capsular polysaccharide of Salmonella enterica subsp. Typhi vaccine by serum bactericidal assay.
    Ahmadi H; Tabaraie B; Maleknia S; Shapouri R; Nejati M; Pour Mirza Gholi F; Hedayati M; Sadati M; Zahednia S; Sharifat Salmani A
    J Med Microbiol; 2013 Feb; 62(Pt 2):283-286. PubMed ID: 23105026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.